Jason M. Broderick
OncLive.com
Plainsboro Township, NJ, United States
Contact Jason
Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.
| Recent: |
|
| Past: |
|
Past articles by Jason:
PSA Response Following Darolutamide Triplet Linked to OS Benefit in mHSPC
Treatment with darolutamide, androgen deprivation therapy, and docetaxel that elicited a PSA response was linked to improved overall survival in patients with metastatic hormone-sensitive prostate cancer. → Read More
Obese Patients Tend to Have Better Prostate Cancer Outcomes
Despite this “obesity paradox,” doctors do not recommend gaining weight with hopes of improving cancer outcomes. → Read More
NCCN Adds Rucaparib to Prostate Cancer Guidelines
The National Comprehensive Cancer Network has updated its Prostate Cancer guidelines to include the PARP inhibitor rucaparib. → Read More
Avelumab Extends Survival as Frontline Maintenance in Urothelial Carcinoma
Adding avelumab to best supportive care improved the median overall survival by over 7 months in patients with locally advanced or metastatic urothelial carcinoma, according to findings from the phase 3 JAVELIN Bladder 100 study. → Read More
FDA Waives ODAC Review of Margetuximab in HER2+ Breast Cancer
The FDA’s Oncologic Drugs Advisory Committee will no longer be meeting to review a Biologics License Application for margetuximab for the treatment of patients with HER2-positive breast cancer. → Read More
Ipatasertib Survival Results Continue to Impress in TNBC
Adding ipatasertib to paclitaxel continued to demonstrate a clinically meaningful extension in overall survival in patients with triple-negative breast cancer. → Read More
Acalabrutinib Long-Term Benefit in CLL Captured in Published Data
The benefit of single-agent acalabrutinib continued well over 3 years after treatment initiation in patients with relapsed/refractory chronic lymphocytic leukemia. → Read More
FDA Grants Priority Review to Nivolumab/Ipilimumab Plus Chemo in Frontline NSCLC
The FDA has granted a priority review designation to nivolumab plus ipilimumab and chemotherapy for use as a frontline treatment for patients with metastatic or recurrent non–small cell lung cancer. → Read More
Tocilizumab Successfully Treats COVID-19 in Patient With Myeloma
The oncology supportive care agent tocilizumab might effectively treat cytokine storm caused by COVID-19 in patients with blood cancers, according to a case study of a patient with multiple myeloma. → Read More
Deep Data Dive Needed for Upfront Treatment Selection in iNHL
At the 24th Annual International Congress on Hematologic Malignancies®, Sonali M. Smith, MD, University of Chicago Medicine, detailed the critical clinical trial findings currently informing treatment selection in the frontline indolent non-Hodgkin lymphoma paradigm. → Read More
FDA Accepts BLA for Subcutaneous Fixed-Dose Pertuzumab/Trastuzumab in HER2+ Breast Cancer
The FDA has accepted a Biologics License Application for a fixed-dose combination of pertuzumab and trastuzumab with hyaluronidase, administered by subcutaneous injection in combination with intravenous chemotherapy, for the treatment of eligible patients with HER2-positive breast cancer. → Read More
Neoadjuvant Durvalumab Regimen Shows Promise in TNBC
A durvalumab-based neoadjuvant regimen induced an impressive pathologic complete response rate in patients with triple-negative breast cancer. → Read More
Extended Follow-Up Shows Continued Olaparib Benefit in BRCA+ MBC
Olaparib continued to show a numerical overall survival (OS) benefit with a favorable hazard ratio for OS versus chemotherapy in patients with BRCA-positive, HER2-negative metastatic breast cancer, according to an extended, exploratory follow-up analysis of the phase III OlympiAD trial. → Read More
FDA Issues Warning on Severe Lung Inflammation With CDK4/6 Inhibitors in Breast Cancer
The FDA is updating the prescribing information and Patient Package Insert for CDK4/6 inhibitors to include a warning that the treatments in rare cases may cause severe inflammation of the lungs. → Read More
Atezolizumab Combo Shows Clinical OS Benefit in PD-L1-High Squamous NSCLC
The addition of atezolizumab (Tecentriq) to carboplatin and nab-paclitaxel (Abraxane) showed a clinical overall survival benefit among a subgroup of patients with advanced squamous non–small cell lung cancer. → Read More
FDA Delays Decision on Frontline Atezolizumab Plus Carboplatin/Nab-Paclitaxel in Nonsquamous NSCLC
The FDA has extended the review period for a supplemental biologics license application for atezolizumab for use in combination with carboplatin and nab-paclitaxel as a first-line treatment for patients with metastatic nonsquamous non–small cell lung cancer who do not have EGFR or ALK aberrations. → Read More
TAS-102 Nabs Japanese Approval for Gastric Cancer
The Japanese Ministry of Health, Labour and Welfare has approved TAS-102 (trifluridine/tipiracil; Lonsurf) for the treatment of patients with unresectable advanced or recurrent gastric cancer that has progressed after chemotherapy. → Read More
Daratumumab/VMP Combo Approved in Japan for Frontline Myeloma
The Japanese Ministry of Health, Labor and Welfare has approved daratumumab for use in combination with bortezomib, melphalan, and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. → Read More
Pyrotinib Combo Delays Progression in Heavily Pretreated HER2+ Breast Cancer
Combining pyrotinib with capecitabine reduced the risk of disease progression or death by 64% compared with lapatinib (Tykerb) plus capecitabine in Chinese patients with relapsed or metastatic HER2-positive breast cancer. → Read More
Frontline Atezolizumab Combo Improves PFS in Phase III Bladder Cancer Trial
Adding atezolizumab to platinum-based chemotherapy significantly improved progression-free survival in patients with previously untreated locally advanced or metastatic urothelial carcinoma, according to results from the phase III IMvigor130 study. → Read More